Correction: Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives

被引：0
|
作者：
Mabel Aoun
Elie Helou
Ghassan Sleilaty
Rony M. Zeenny
Dania Chelala
机构：
[1] Saint-Joseph University,Department of Nephrology, Faculty of Medicine
[2] Saint-George Hospital,Department of Nephrology
[3] Saint-Joseph University,Department of Urology, Faculty of Medicine
[4] Saint-Joseph University,Unit of biostatistics, Faculty of Medicine
[5] Pharmacy Director,Department of Nephrology at Hotel
[6] American University of Beirut Medical Center,Dieu de France Hospital, Faculty of Medicine
[7] Saint-Joseph University,undefined
来源：
BMC Health Services Research | / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives (vol 22, 586, 2022)
    Aoun, Mabel
    Helou, Elie
    Sleilaty, Ghassan
    Zeenny, Rony M.
    Chelala, Dania
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [2] COST OF ILLNESS OF CHRONIC KIDNEY DISEASE IN LEBANON: FROM THE SOCIETAL PERSPECTIVE
    Aoun, Mabel
    Helou, Elie
    Sleilaty, Ghassan
    Chelala, Dania Nehme
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [3] Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer
    Eandi, Mario
    Gandini, Giorgio
    Povero, Massimiliano
    Zaniolo, Orietta
    Pradelli, Lorenzo
    Aprili, Giuseppe
    BLOOD TRANSFUSION, 2015, 13 (01) : 37 - 45
  • [4] Third-party payer cost of atopic dermatitis and eczema in the United States
    Ellis, C
    Drake, L
    Prendergast, M
    Abramovits, W
    Boguniewicz, M
    Daniel, C
    Lebwohl, M
    Stevens, S
    Whitaker-Worth, D
    Tong, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 531 - 531
  • [5] COST-BENEFIT ANALYSIS OF BARIATRIC SURGERY FROM A PRIVATE AND PUBLIC THIRD-PARTY PAYER PERSPECTIVE IN CHILE
    Bitran, R.
    Russo, M.
    Santosh, A.
    Hovermale, B.
    Valencia, J.
    VALUE IN HEALTH, 2019, 22 : S220 - S220
  • [6] COST EFFECTIVENESS ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY FOR HEART FAILURE FROM A PUBLIC THIRD-PARTY PAYER PERSPECTIVE IN CHILE
    Bitran, R.
    Russo, M.
    May, D.
    Valencia, J.
    VALUE IN HEALTH, 2019, 22 : S217 - S218
  • [7] Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
    Tsai, Naoky
    Jeffers, Lennox
    Cragin, Lael
    Sorensen, Sonja
    Su, Wenqing
    Rosenblatt, Lisa
    Tang, Hong
    Hebden, Tony
    Juday, Timothy
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 227 - 235
  • [8] A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective
    Xu, Xiao
    Schaefer, Caroline
    Szende, Agota
    Genofre, Eduardo
    Katial, Rohit
    Chung, Yen
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (11): : 1193 - 1204
  • [9] Costs of hypertension in Poland measured from the third party payer perspective in comparison with the societal perspective
    Hermanowski, T
    Jaworski, R
    Czech, M
    Pachocki, R
    VALUE IN HEALTH, 2004, 7 (06) : 690 - 690
  • [10] A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US
    Charles, Meaghan St.
    Minshall, Michael E.
    Pandya, Bhavik J.
    Baran, Robert W.
    Tunis, Sandra L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (06) : 1343 - 1353
12345